Research progress on effect of Helicobacter pylori on immune checkpoint inhibitors of gastric cancer
10.3969/j.issn.1000-484X.2025.03.038
- VernacularTitle:幽门螺杆菌对胃癌免疫检查点抑制剂疗效影响的研究进展
- Author:
Matu LI
1
;
Ya ZHENG
;
Jinyu ZHAO
;
Xiaochuang SHU
;
Qiang LI
;
Yuping WANG
;
Yongning ZHOU
Author Information
1. 兰州大学第一临床医学院,兰州 730000;兰州大学第一医院消化科,兰州 730000;兰州大学第一医院,甘肃省消化系疾病临床医学研究中心,兰州 730000
- Publication Type:Journal Article
- Keywords:
Gastric cancer;
Helicobacter pylori;
Immune checkpoint inhibitors;
PD-1/PD-L1;
Immunotherapy
- From:
Chinese Journal of Immunology
2025;41(3):727-732
- CountryChina
- Language:Chinese
-
Abstract:
Gastric cancer is a malignant tumor of the digestive system with strong invasiveness and a high metastasis rate.Its morbidity and mortality rank among the top five in the world and the prognosis is closely related to the disease stage.Multidisciplinary comprehensive treatment based on systemic antitumor drugs is generally adopted in patients with advanced or metastatic gastric can-cer,but the prognosis is typically poor.With the in-depth research on the tumor microenvironment,the development of multi-omics technology,and the application of immunotherapy and neoadjuvant chemoradiotherapy,the therapeutic effect of advanced gastric can-cer has been initially improved,and immunotherapy has become the most potential of the treatment strategies.Many studies have found that Helicobacter pylori(Hp)infection status is closely related to the efficacy of immunotherapy for gastric cancer,especially im-mune checkpoint inhibitors(ICIs),but there is not clear whether it has advantages or disadvantages.This article reviews the current research on the efficacy of Hp on ICIs in advanced gastric cancer to provide ideas for further research on the interaction between Hp in-fection and tumor immunotherapy.
